Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments close on Thursday 22 January at 4:30pm because of system upgrades. We expect to open them again on Friday 23 January  at 8am the latest.

Dual-use blood sampling device for modern defense and disaster medicine - InstaSep™

Reference number
Coordinator SampleFacts AB
Funding from Vinnova SEK 1 000 000
Project duration November 2025 - August 2026
Status Ongoing
Venture Civil-military synergies
Call Acceleration of civil-military innovations by 2025

Purpose and goal

The project aims to establish the SampleFacts InstaSep™ blood separation device as a dual-use application platform for biosafety and defense medicine as well as serving civilian markets. The purpose is to enable rapid, reliable plasma separation without centrifugation, directly at the point of sampling, even under rigid conditions. The objective is to demonstrate that InstaSep™ can support field diagnostics, and monitoring when conventional sampling infrastructure is unavailable.

Expected effects and result

The outcome of the project is to adapt and validate the InstaSep™ for diverse biomarker applications in both in civilian systems, humanitarian operations, and military medicine contexts to demonstrate the dual-use applicability in decentralized diagnostics. By enabling immediate separation of blood, InstaSep™ enables retrospective analysis, since both fractions remain stable at ambient temperature. Transport of the samples requires neither cold chain nor any biohazardous liquid handling.

Planned approach and implementation

The nine-month project comprises three phases. Phase 1 will assess feasibility through user interviews in military and civilian settings, definition of operational requirements, and conducting market and regulatory analyses. In phase 2, validation of performance and analyte stability of InstaSep™ under extreme conditions will be performed. Phase 3 will include pilot testing, market entry planning, and risk mitigation.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 17 November 2025

Reference number 2025-03492